DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.

Francisco J Cueto Carlos Del Fresno Sánchez Paola BrandiAlexis J CombesElena Hernández-GarcíaAlfonso R Sánchez-PauleteMichel EnamoradoChristian P BromleyManuel J Jose GómezRuth Conde-GarrosaSantos Mañes Santiago Zelenay Ignacio Melero Bermejo Salvador Iborra Matthew F Krummel David Sancho

Published in: Journal for immunotherapy of cancer (2022)

DNGR-1 limits the accumulation of tumor-infiltrating cDC1s promoted by Flt3L. Thus, DNGR-1 blockade may improve antitumor immunity in tumor therapy settings associated to high Flt3L expression.

Keyphrases

acute myeloid leukemia
dendritic cells
tyrosine kinase
poor prognosis
immune response
regulatory t cells
cell cycle
stem cells
binding protein
mesenchymal stem cells
cell therapy